[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611871":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":23,"locations":29,"responsibleParty":108,"collaborators":110,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":10,"eligibilityCriteria":120,"healthyVolunteers":116,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":10,"studyType":127,"phases":10,"briefSummary":128,"conditions":129,"keywords":137,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},{"fullName":5,"class":6},"Resonance, Inc.","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"All Cancer Diagnoses",null,"Patients aged 0-21 years with any type of cancer diagnosis. Retrospective medical record review will capture incidence of treatment failure, including relapse, progression, or abandonment.",[13],"Other: Retrospective Medical Record Review",{"label":15,"type":10,"description":16,"interventionNames":17},"Acute Lymphoblastic Leukemia \u002F Lymphoblastic Lymphoma","Patients aged 0-21 years diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. Retrospective review will focus on therapy-related toxicities and treatment outcomes in this subgroup.",[13],[19],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"Retrospective Medical Record Review","This study involves retrospective review of medical records of pediatric, adolescent, and young adult cancer patients (ages 0-21 years) treated at participating oncology centers in Guatemala, Honduras, El Salvador, Armenia, and Tanzania. No experimental drug, device, or behavioral intervention is being administered. Data abstraction will be performed to assess treatment failure, therapy-related toxicities, and clinical outcomes.",[15,9],[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Gabriela Villanueva, MD.","CONTACT","+1-901-205-9518","gabriela.villanueva@resonancehealth.org",[30,47,62,78,94],{"facility":31,"status":32,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Yeolyan Center for Cancer and Blood Disorders","RECRUITING","Yerevan","Armenia","AM",{"type":37,"coordinates":38},"Point",[39,40],44.5126,40.17765,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":45,"phoneExt":10,"email":46},"Anna Avagyan, MD","+010283800","avagyananna2010@gmail.com",{"facility":48,"status":49,"city":50,"state":50,"zip":51,"country":50,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Fundación Ayúdame a Vivir","NOT_YET_RECRUITING","El Salvador","1101","SV",{"type":37,"coordinates":54},[55,56],-87.70194,13.20306,{"lat":56,"lon":55},[59],{"name":60,"role":26,"phone":10,"phoneExt":10,"email":61},"Roberto Vasquez, MD.","rfranklinvz@gmail.com",{"facility":63,"status":32,"city":64,"state":10,"zip":10,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Unidad Nacional de Oncología Pediátrica (UNOP)","Guatemala City","Guatemala","GT",{"type":37,"coordinates":68},[69,70],-90.51327,14.64072,{"lat":70,"lon":69},[73],{"name":74,"role":26,"phone":75,"phoneExt":76,"email":77},"Jeanine Alfaro, MD","50223177800","502","jalfaroflowcyt@ayuvi.org.gt",{"facility":79,"status":49,"city":80,"state":81,"zip":82,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Hospital Mario Catarino Rivas","San Pedro Sula","Cortés Department","21102","Honduras","HN",{"type":37,"coordinates":86},[87,88],-88.02588,15.50585,{"lat":88,"lon":87},[91],{"name":92,"role":26,"phone":10,"phoneExt":10,"email":93},"Roxana Martinez, MD.","roxmartinez@doctor.com",{"facility":95,"status":49,"city":96,"state":97,"zip":98,"country":83,"countryCode":84,"cosmosGeoPoint":99,"geoPoint":103,"contacts":104},"Hospital Escuela","Tegucigalpa","Distrito Central","11101",{"type":37,"coordinates":100},[101,102],-87.20681,14.0818,{"lat":102,"lon":101},[105],{"name":106,"role":26,"phone":10,"phoneExt":10,"email":107},"Ligia Fu, MD.","ligiafucarrasco@yahoo.com",{"type":109,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[111],{"name":112,"class":113},"Servier Affaires Médicales","INDUSTRY","100611871","caya-cancer-retrospective-cohort-study-100611871",false,"NCT07246213","CAYA Cancer Retrospective Cohort Study","Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries","Inclusion Criteria:\n\nSubjects must meet all the following criteria to be included in this registry:\n\n1. Participants must be willing and able to provide informed consent prior to enrollment in the registry.\n\n   1. For minors or individuals unable to provide informed consent, assent must be obtained along with consent from a legal guardian.\n   2. Note: Exemption applies to this criterion when waiver of informed consent\u002Fassent is granted by Institutional Review Board(IRB)\u002FIndependent Ethics Committee(IEC)\u002FCompetent Authorities(CAs).\n2. A confirmed diagnosis of any type of cancer within the 15 years prior to the site's activation date.\n3. Age 0 to 21 years at the time of diagnosis.\n4. Received substantial anti-cancer treatment at the participating center, including but not limited to:\n\n   1. Chemotherapy\n   2. Surgery\n   3. Radiation therapy\n   4. Immunotherapy\n5. Medical records are available and accessible for review\n\nExclusion Criteria:\n\n* Subjects meeting any of the following criteria will be excluded from this registry:\n\n  1. Patients who only visited the participating center for:\n\n     1. Consultation without subsequent primary anti-cancer treatment at the participating center\n     2. Pathology, radiology, or other diagnostic evaluations without treatment","ALL","0 Years","21 Years",{"count":125,"type":126},18000,"ESTIMATED","OBSERVATIONAL","Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies.\n\nAcute lymphoblastic leukemia(ALL)\u002Flymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare.\n\nThis study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia\u002Flymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.",[130,131,132,133,134,135,136],"Acute Lymphoblastic Leukemia","Lymphoblastic Lymphoma","Young Adult Cancer","Adolescent Cancer","Childhood Cancers","Acute Lymphoblastic Leukemia (ALL)","Lymphoblastic Lymphoma (LBL)",[138,139,140,141,142,143,144,145,146,147],"Cancer outcomes","Low- and Middle-Income Countries (LMICs)","Childhood cancer","Adolescent and young adult cancer (CAYA)","Treatment failure","Therapy-related toxicities","Retrospective cohort","Leukemia outcomes","Oncology disparities","High-Income Countries (HICs)","2025-12-12",{"date":150,"type":151},"2025-12-19","ACTUAL",{"date":153,"type":151},"2025-06-04",{"date":155,"type":126},"2028-12-04",{"name":5,"class":6},5]